BR9915139A - Método de inibir a hiperpermeabilidade vascular, e de inibir um processo ou estado fisiológico em um indivìduo - Google Patents
Método de inibir a hiperpermeabilidade vascular, e de inibir um processo ou estado fisiológico em um indivìduoInfo
- Publication number
- BR9915139A BR9915139A BR9915139-1A BR9915139A BR9915139A BR 9915139 A BR9915139 A BR 9915139A BR 9915139 A BR9915139 A BR 9915139A BR 9915139 A BR9915139 A BR 9915139A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibiting
- tyrosine kinase
- vascular hyperpermeability
- individual
- events
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Abstract
"MéTODO DE INIBIR A HIPERPERMEABILIDADE VASCULAR, E DE INIBIR UM PROCESSO OU ESTADO FISIOLóGICO EM UM INDIVìDUO" A hiperpermeabilidade vascular em indivíduos é um prelúdio para diversos eventos fisiológicos que são freq³entemente nocivos. Entre estes eventos está a formação de edema, diapedese, mudança transendotelial aberrante, extravasação, exsudação e efusão, deposição de matriz (freq³entemente com a proliferação estromal anormal) e hipotensão vascular. A hiperpermeabilidade vascular e os eventos subsequentes podem ser inibidos pela administração de um composto que inibe a atividade da enzima do receptor de tirosina cinase de VEGF conhecido como receptor de tirosina cinase de KDR. Os compostos administrados preferidos inibem seletivamente a função da tirosina cinase KDR mas não bloqueiam a atividade da tirosina cinase de Flt-1 que é um outro receptor de tirosina cinase de VEGF.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10746298P | 1998-11-06 | 1998-11-06 | |
PCT/US1999/025903 WO2000027414A2 (en) | 1998-11-06 | 1999-11-03 | Inhibition of the formation of vascular hyperpermeability |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9915139A true BR9915139A (pt) | 2001-08-07 |
Family
ID=22316735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9915139-1A BR9915139A (pt) | 1998-11-06 | 1999-11-03 | Método de inibir a hiperpermeabilidade vascular, e de inibir um processo ou estado fisiológico em um indivìduo |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1126842A2 (pt) |
JP (1) | JP2002529421A (pt) |
KR (1) | KR20010080952A (pt) |
CN (1) | CN1342077A (pt) |
AR (1) | AR023912A1 (pt) |
AU (1) | AU1908000A (pt) |
BG (1) | BG105476A (pt) |
BR (1) | BR9915139A (pt) |
CA (1) | CA2347916A1 (pt) |
CO (1) | CO5150183A1 (pt) |
CZ (1) | CZ20011564A3 (pt) |
HU (1) | HUP0104302A3 (pt) |
ID (1) | ID29063A (pt) |
IL (1) | IL142583A0 (pt) |
NO (1) | NO20012218L (pt) |
PL (1) | PL348163A1 (pt) |
SK (1) | SK5052001A3 (pt) |
TR (1) | TR200102278T2 (pt) |
WO (1) | WO2000027414A2 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140173B2 (en) * | 1998-12-22 | 2013-04-03 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
EP1250155B1 (en) * | 1999-12-22 | 2008-04-16 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
DE10021246A1 (de) * | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
CA2454976C (en) * | 2001-07-26 | 2011-05-10 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
EP2284180B1 (en) | 2003-03-03 | 2015-09-09 | Dyax Corp. | Uses of peptides that specifically bind HGF receptor (cMET) |
DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
KR20100027091A (ko) | 2006-11-15 | 2010-03-10 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
RU2013102545A (ru) | 2010-07-28 | 2014-09-10 | Алкон Ресерч, Лтд. | Связывающая vegfa си-рнк и способы лечения in vivo |
KR101565886B1 (ko) | 2013-10-23 | 2015-11-05 | 전남대학교산학협력단 | 난소과자극증후군의 진단 방법 및 키트 |
EP3183346A4 (en) | 2014-08-22 | 2018-10-24 | Auckland Uniservices Limited | Channel modulators |
CN106381330A (zh) * | 2016-08-30 | 2017-02-08 | 张建华 | 一种检测交通性脑积水易感性的引物及试剂盒 |
KR102644938B1 (ko) * | 2018-03-19 | 2024-03-07 | 주식회사 파멥신 | 항-vegfr-2 항체 |
CN109718253B (zh) * | 2019-01-16 | 2021-09-24 | 中国人民解放军总医院 | 一种代谢产生组胺的菌在预防或治疗高原病中的用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE789948A (fr) * | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
US3843664A (en) * | 1973-02-20 | 1974-10-22 | Sandoz Ag | Substituted naphtho pyrazoles |
US3843665A (en) * | 1973-04-11 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US3843666A (en) * | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1998033917A1 (en) * | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
FR2742662B1 (fr) * | 1995-12-21 | 1998-01-23 | Centre Nat Rech Scient | Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
DE19638745C2 (de) * | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
US6204011B1 (en) * | 1997-06-18 | 2001-03-20 | Merck & Co., Inc. | Human receptor tyrosine kinase, KDR |
AU9691198A (en) * | 1997-10-06 | 1999-04-27 | Basf Aktiengesellschaft | Indeno{1,2-c}-, naphtho{1,2-c}- and benzo{6,7}cyclohepta{1,2-c}pyrazole derivatives |
JP2001518502A (ja) * | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | チロシンキナーゼ活性を阻害するためのインデノ[1,2−c]ピラゾール誘導体 |
DE69918542T2 (de) * | 1998-04-30 | 2005-08-18 | Abbott Gmbh & Co. Kg | Substituierte trizyklische pyrazolderivate mit protein kinase aktivität |
-
1999
- 1999-11-03 CZ CZ20011564A patent/CZ20011564A3/cs unknown
- 1999-11-03 HU HU0104302A patent/HUP0104302A3/hu unknown
- 1999-11-03 BR BR9915139-1A patent/BR9915139A/pt not_active IP Right Cessation
- 1999-11-03 CA CA002347916A patent/CA2347916A1/en not_active Abandoned
- 1999-11-03 TR TR2001/02278T patent/TR200102278T2/xx unknown
- 1999-11-03 ID IDW00200101000A patent/ID29063A/id unknown
- 1999-11-03 KR KR1020017005724A patent/KR20010080952A/ko not_active Application Discontinuation
- 1999-11-03 EP EP99962685A patent/EP1126842A2/en not_active Withdrawn
- 1999-11-03 AU AU19080/00A patent/AU1908000A/en not_active Abandoned
- 1999-11-03 SK SK505-2001A patent/SK5052001A3/sk unknown
- 1999-11-03 JP JP2000580643A patent/JP2002529421A/ja active Pending
- 1999-11-03 PL PL99348163A patent/PL348163A1/xx unknown
- 1999-11-03 CN CN99812924A patent/CN1342077A/zh active Pending
- 1999-11-03 IL IL14258399A patent/IL142583A0/xx unknown
- 1999-11-03 WO PCT/US1999/025903 patent/WO2000027414A2/en not_active Application Discontinuation
- 1999-11-05 AR ARP990105608A patent/AR023912A1/es unknown
- 1999-11-08 CO CO99070343A patent/CO5150183A1/es unknown
-
2001
- 2001-04-25 BG BG105476A patent/BG105476A/xx unknown
- 2001-05-04 NO NO20012218A patent/NO20012218L/no unknown
Also Published As
Publication number | Publication date |
---|---|
BG105476A (en) | 2002-02-28 |
NO20012218D0 (no) | 2001-05-04 |
AR023912A1 (es) | 2002-09-04 |
WO2000027414A2 (en) | 2000-05-18 |
CN1342077A (zh) | 2002-03-27 |
CZ20011564A3 (cs) | 2002-04-17 |
HUP0104302A3 (en) | 2002-11-28 |
KR20010080952A (ko) | 2001-08-25 |
PL348163A1 (en) | 2002-05-06 |
HUP0104302A2 (hu) | 2002-03-28 |
IL142583A0 (en) | 2002-03-10 |
NO20012218L (no) | 2001-06-18 |
WO2000027414A3 (en) | 2000-09-08 |
EP1126842A2 (en) | 2001-08-29 |
TR200102278T2 (tr) | 2001-12-21 |
JP2002529421A (ja) | 2002-09-10 |
ID29063A (id) | 2001-07-26 |
CA2347916A1 (en) | 2000-05-18 |
CO5150183A1 (es) | 2002-04-29 |
SK5052001A3 (en) | 2002-10-08 |
AU1908000A (en) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9915139A (pt) | Método de inibir a hiperpermeabilidade vascular, e de inibir um processo ou estado fisiológico em um indivìduo | |
Trivedi et al. | Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. | |
BR0312648A (pt) | Processo para preparação de certos compostos pirrolo triazina | |
Romero et al. | Regulation of sensitivity to beta-adrenergic stimulation in induction of pineal N-acetyltransferase. | |
BRPI0012352B8 (pt) | compostos de indazol ou sal farmaceuticamente aceitável e composição farmacêutica | |
DE59712501D1 (de) | 1-benzyl-3-(substituiertes-hetaryl)-kondensierten pyrazol-derivaten zur behandlung von erkrankungen des herz-kreislaufsystems und des zentralnervensystems | |
Opie | Calcium channel antagonists, part I: Fundamental properties: Mechanisms. classification, sites of action | |
ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
ES2164366T3 (es) | Derivados de la distamicina acriloil sustituidos, procedimiento de fabricacion asociado y su utilizacion como agentes antitumorales y antivirales. | |
Hjorth et al. | (−)-Pindolol stereospecifically inhibits rat brain serotonin (5-HT) synthesis | |
Weinstock | The presynaptic effect of β-adrenoceptor antagonists on noradrenergic neurones | |
Bennett et al. | The effect of nucleotides and adenosine on stimulus‐evoked glutamate release from rat brain cortical slices | |
Bohmann et al. | P2‐receptor modulation of noradrenergic neurotransmission in rat kidney | |
Cox et al. | Prejunctional angiotensin receptors involved in the facilitation of noradrenaline release in mouse tissues | |
Langer et al. | Physiological and pharmacological role of the regulation of noradrenaline release by presynaptic dopamine receptors in the peripheral nervous system | |
ES2036560T3 (es) | Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. | |
Hilakivi et al. | Effects of serotonin and noradrenaline uptake blockers on wakefulness and sleep in cats | |
MY107354A (en) | Substituted cyclohexenes as central nervous system agents | |
Wolf et al. | Effects of 5, 6‐Dihydroxytryptamine on the Release, Synthesis, and Storage of Serotonin: Studies Using Rat Brain Synaptosomes | |
Dominic et al. | Depression of behavior and the brain content of α-methylnorepinephrine and α-methyldopamine following the administration of α-methyldopa | |
Mutafova-Yambolieva et al. | Endothelin-3 can both facilitate and inhibit transmitter release in the guinea-pig vas deferens | |
Bassenge | Physiologie der Koronardurchblutung | |
Vanhoutte | Serotonergic antagonists and vascular disease | |
Zheng et al. | Relaxant effects of matrine on aortic smooth muscles of guinea pigs | |
Siggins et al. | Cytochemical and physiological evidence for cholinergic, neurogenic vasodilation of amphibian arterioles and precapillary sphincters: I. Light microscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Free format text: ABBOTT GMBH & CO. KG (DE) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007. |